Granulocyte Colony-Stimulating Factor
"Granulocyte Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.
| Descriptor ID |
D016179
|
| MeSH Number(s) |
D12.644.276.374.410.240.350 D12.776.395.240.200 D12.776.467.374.410.240.350 D23.529.374.410.240.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Granulocyte Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 2 | 4 |
| 1997 | 1 | 1 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 2 | 2 | 4 |
| 2008 | 1 | 2 | 3 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 3 | 4 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 1 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Granulocyte Colony-Stimulating Factor" by people in Profiles.
-
Chitosan-Based Dressing as a Sustained Delivery System for Bioactive Cytokines. Int J Mol Sci. 2023 Dec 19; 25(1).
-
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study. Haematologica. 2023 08 01; 108(8):2249-2254.
-
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 04; 29(4):869-879.
-
Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens. Am J Hematol. 2023 03; 98(3):E53-E56.
-
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10.
-
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplant Cell Ther. 2023 01; 29(1):37.e1-37.e7.
-
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am J Hematol. 2022 11; 97(11):1427-1434.
-
Plasma protein biomarkers for primary graft dysfunction after lung transplantation: a single-center cohort analysis. Sci Rep. 2022 09 27; 12(1):16137.
-
Successful haematopoietic progenitor cell collection by plerixafor in combination with reduced dose granulocyte colony-stimulating factor for severe hypoxemia provoked by high-dose granulocyte colony-stimulating factor administration. Transfus Med. 2022 12; 32(6):527-529.
-
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. Pediatr Blood Cancer. 2022 10; 69(10):e29812.